Mirati Therapeutics, Inc. (the “Company” or “Mirati”) is a clinical-stage biotechnology company whose mission is to discover, design and deliver breakthrough therapies to transform the lives of patients with cancer and their loved ones. The Company is focused on bringing forward therapies that address areas of high unmet need, including lung cancer, and advancing a pipeline of therapeutics targeting the genetic and immunological drivers of cancer. Mirati is using its scientific expertise to develop solutions in two registration-enabling programs: adagrasib (MRTX849), an investigational small molecule, potent and selective KRASG12C inhibitor, as monotherapy and in combination with other agents, and sitravatinib, an investigational spectrum-selective inhibitor of receptor tyrosine kinases in combination with checkpoint inhibitor therapies. Mirati is also advancing its differentiated preclinical portfolio, including MRTX1133, an investigational KRASG12D inhibitor, MRTX1719, an investigational PRMT5 inhibitor, and other oncology discovery programs.